Market Overview

Zogenix Sees Q4 Sales of $13.4M, Unit Volume Up 9% QoQ; Cited Effect from Hurricane Sandy

Related ZGNX
Zogenix Announces New Efficacy Data from Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study

Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales for the quarter ended December 31, 2012. Zogenix expects to report fourth quarter 2012 gross product sales of approximately $13.5 million on 145,200 units shipped, with unit volume up approximately 9% sequentially from third quarter 2012 and 26% from fourth quarter 2011.

For the full year 2012, Zogenix announced preliminary unaudited net product revenue of approximately $36 million, up approximately 18% over 2011 and slightly below previously issued guidance of $37 million for 2012.

Preliminary unaudited cash and cash equivalents as of December 31, 2012 were approximately $41.2 million.

Posted-In: News Guidance


Related Articles (ZGNX)

Around the Web, We're Loving...